Clinical Trial Update: Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy trial of vintafolide (EC145) with or without paclitaxel versus paclitaxel alone in triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Vintafolide (EC145) (vintafolide)

Snippet

Sponsor: Endocyte | Conditions: Breast Neoplasms | Phase 2 | Status: WITHDRAWN